| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDC25HU2; CDC25M2; Dual specificity phosphatase Cdc25B; EC 3.1.3.48; M-phase inducer phosphatase 2; MPIP2;;CDC25B |
| WB Predicted band size | Calculated MW: 65 kDa ; Observed MW: 64 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human CDC25B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Cdc25B抗体的3篇参考文献，按文献名称、作者和摘要内容概括列举：
---
1. **文献名称**: "Cdc25B is a prognostic biomarker in multiple human cancers"
**作者**: Boutros R. et al. (2007)
**摘要**: 该研究利用特异性Cdc25B抗体，通过免疫组化分析了多种癌症组织中Cdc25B的表达水平，发现其高表达与肿瘤进展和患者预后不良显著相关，提示其作为癌症预后标志物的潜力。
---
2. **文献名称**: "Subcellular localization of Cdc25B phosphatase isoforms depends on distinct N-terminal regulatory domains"
**作者**: Crémer T. et al. (2015)
**摘要**: 通过构建Cdc25B不同剪接变体的表达载体，结合Cdc25B抗体进行免疫荧光和Western blot分析，揭示了其N端结构域调控亚细胞定位的机制，为理解Cdc25B在细胞周期中的分区功能提供依据。
---
3. **文献名称**: "Cdc25B and Cdc25C inhibition in cancer therapy: A double-edged sword?"
**作者**: Kristjansdottir K., Rudolph J. (2004)
**摘要**: 研究探讨了靶向Cdc25B/C的小分子抑制剂及抗体的治疗潜力，指出特异性Cdc25B抗体可抑制其磷酸酶活性，但需平衡对正常细胞的毒性，为癌症靶向治疗策略提供理论参考。
---
以上文献均涉及Cdc25B抗体的应用，涵盖其在癌症诊断、亚细胞功能研究及靶向治疗中的角色。如需具体文章链接或补充，可进一步提供数据库检索信息。
The Cdc25B antibody is a crucial tool in studying the Cdc25B phosphatase, a member of the Cdc25 family involved in cell cycle regulation. Cdc25B specifically dephosphorylates and activates cyclin-dependent kinases (CDKs), particularly CDK1. to drive the G2/M phase transition. Its role in checkpoint regulation and potential oncogenic properties make it a focus in cancer research. Overexpression of Cdc25B is linked to genomic instability, tumor progression, and therapy resistance in various cancers, including breast, lung, and colorectal.
Cdc25B antibodies enable detection and quantification of the protein in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use these antibodies to explore Cdc25B's expression patterns, subcellular localization, and interactions with regulatory proteins (e.g., kinases, ubiquitin ligases). Commercial antibodies vary in clonal specificity, epitope recognition, and cross-reactivity with paralogs Cdc25A/C, necessitating validation via knockout controls or siRNA.
Studies employing Cdc25B antibodies have highlighted its potential as a therapeutic target, with inhibitors under investigation for anticancer applications. Additionally, its expression levels in tumors are being evaluated as prognostic biomarkers. Ongoing research aims to clarify isoform-specific functions, post-translational modifications, and context-dependent roles in normal vs. malignant cells, underscoring the antibody's importance in both basic and translational biology.
×
